Kodiak Sciences Inc. Forecasted to Post FY2024 Earnings of ($3.63) Per Share (NASDAQ:KOD)

Kodiak Sciences Inc. (NASDAQ:KOD) – Equities research analysts at Zacks Research upped their FY2024 earnings per share estimates for Kodiak Sciences in a research note issued on Tuesday, September 3rd. Zacks Research analyst R. Department now anticipates that the company will post earnings per share of ($3.63) for the year, up from their previous forecast of ($3.76). The consensus estimate for Kodiak Sciences’ current full-year earnings is ($3.58) per share. Zacks Research also issued estimates for Kodiak Sciences’ Q4 2024 earnings at ($0.96) EPS, Q1 2025 earnings at ($0.91) EPS, Q2 2025 earnings at ($0.83) EPS, Q3 2025 earnings at ($0.97) EPS, Q4 2025 earnings at ($1.01) EPS, FY2025 earnings at ($3.73) EPS, Q1 2026 earnings at ($0.53) EPS, Q2 2026 earnings at ($0.45) EPS and FY2026 earnings at ($1.78) EPS.

Separately, HC Wainwright assumed coverage on Kodiak Sciences in a research note on Thursday. They set a “neutral” rating and a $3.00 price target on the stock. Two analysts have rated the stock with a sell rating, two have issued a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $5.00.

Kodiak Sciences Stock Up 2.5 %

Shares of KOD opened at $2.48 on Friday. Kodiak Sciences has a 12-month low of $1.37 and a 12-month high of $7.77. The firm has a market capitalization of $130.29 million, a price-to-earnings ratio of -0.56 and a beta of 2.35. The stock’s 50-day moving average price is $2.67 and its 200 day moving average price is $3.66.

Institutional Investors Weigh In On Kodiak Sciences

Institutional investors have recently added to or reduced their stakes in the stock. State Board of Administration of Florida Retirement System acquired a new stake in Kodiak Sciences during the first quarter valued at approximately $86,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Kodiak Sciences during the first quarter valued at approximately $68,000. Vanguard Group Inc. boosted its holdings in Kodiak Sciences by 0.7% during the first quarter. Vanguard Group Inc. now owns 1,654,448 shares of the company’s stock valued at $8,702,000 after purchasing an additional 10,978 shares in the last quarter. Diversified Trust Co acquired a new stake in Kodiak Sciences during the first quarter valued at approximately $83,000. Finally, Sei Investments Co. acquired a new stake in Kodiak Sciences during the first quarter valued at approximately $595,000. 89.06% of the stock is owned by institutional investors and hedge funds.

About Kodiak Sciences

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.